Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30611453 | 0.79 | MKNK1 (0.69) | MKNK1ROCK2EGFRFLT1RET | |
| SCHEMBL30611478 | 0.79 | EGFR (0.69) | MKNK1ROCK2EGFRROCK1FLT1 | |
| SCHEMBL13434860 | 0.79 | EGFR (0.69) | MKNK1ROCK2EGFRROCK1FLT1 | |
| SCHEMBL3035598 | 0.78 | ROCK2 (0.60) | MKNK1ROCK2EGFRROCK1FLT1 | |
| SCHEMBL18343172 | 0.78 | ROCK2 (0.61) | MKNK1ROCK2EGFRROCK1FLT1 | |
| SCHEMBL13220452 | 0.73 | ROCK2 (0.55) | MKNK1ROCK2EGFRROCK1FLT1 | |
| SCHEMBL13220420 | 0.73 | ROCK2 (0.55) | MKNK1ROCK2EGFRROCK1FLT1 | |
| SCHEMBL13220435 | 0.73 | CDC7 (0.58) | MKNK1ROCK2EGFRROCK1FLT1 | |
| SCHEMBL13547636 | 0.73 | ROCK2 (0.55) | MKNK1ROCK2EGFRROCK1FLT1 | |
| SCHEMBL13220422 | 0.73 | ROCK2 (0.55) | MKNK1ROCK2EGFRROCK1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228063-B1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORP (US) | 2009-02-11 | — | — | EP | claimed |
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | BAYER HEALTHCARE LLC | 2005-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | KDR, FLT4, FLT1 | MKNK1 1596/4885ROCK2 1390/4885EGFR 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.